Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future


Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab-paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental. This review discusses the evidence behind the currently used regimens, while introducing the potential future of pancreatic cancer care.

Type Journal
ISBN 1444-0903
Authors Pokorny, A. M. J.; Chin, V. T.; Nagrial, A. M.; Yip, D.; Chantrill, L. A.
Responsible Garvan Author Dr Venessa Chin
Published Date 2018-06-01
Published Volume 48
Published Issue 6
Published Pages 637-644
Status Published in-print
DOI 10.1111/imj.13810